X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Efesa (efepoetin alfa) is a bio-better drug for CKD-induced anemia, developed based on hyFc®, Genexine's proprietary long-acting platform technology, which is investigated for the treatment of chronic kidney disease induced anemia in non-dialysis patients.
Lead Product(s): Efepoetin Alfa
Therapeutic Area: Nephrology Product Name: Efesa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kalbe Genexine Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
Genexine’s, GX-H9, a proprietary long-acting growth hormone shows positive topline results from phase 3 study for growth hormone deficiency, is being conducted in China with I-Mab.
Lead Product(s): Eftansomatropin Alfa
Therapeutic Area: Endocrinology Product Name: GX-H9
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: I-Mab Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
GX-188E (tirvalimogene teraplasmid), a DNA vaccine encoding both E6 and E7 antigens of HPV types 16 and 18, which are responsible for about 70% of cervical cancer. It induces antigen-specific CD8 T cell responses by Flt3L fusion.
Lead Product(s): GX-188E,Pembrolizumab
Therapeutic Area: Oncology Product Name: GX-188E
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
GX-188E is a DNA vaccine that encodes the E6/E7 fusion protein of HPV subtypes 16 and 18. Drug induces immune cells to detect E6 and E7 proteins that exist in cervical cancer cells, inducing apoptosis of tumor cells without affecting healthy cells.
Lead Product(s): GX-188E,Pembrolizumab
Therapeutic Area: Oncology Product Name: GX-188E
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2023
Details:
GX-188E is a DNA-based therapeutic vaccine that was discovered and is being developed by Genexine for the treatment of cervical cancer and squamous cell carcinoma of the head and neck.
Lead Product(s): GX-188E,Pembrolizumab
Therapeutic Area: Oncology Product Name: GX-188E
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
The results indicated that GX-I7 (Efineptakin Alfa) in combination with pembrolizumab was safe and well tolerated and demonstrated promising early anti-tumor activity in patients with R/R metastatic TNBC.
Lead Product(s): Efineptakin Alfa,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: GX-I7
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of doses by 2022.
Lead Product(s): GX-19N
Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19N
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Hanmi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 18, 2021
Details:
IPK and Genexine will join forces together to test the protective efficacy of the GX-19N in the regions such as South Africa, where variants mainly appear, utilizing the international collaboration network of Institut Pasteur Korea.
Lead Product(s): GX-19N
Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19N
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Institut Pasteur Korea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 12, 2021
Details:
Through this licensing agreement, KGBio and Genexine aim to develop a and commercialize an immuno-oncology drug GX-I7 (Efineptakin Alpha), namely long-acting interleukin-7 which uses the Genexine hyFc technology platform.
Lead Product(s): Efineptakin alfa
Therapeutic Area: Oncology Product Name: GX-I7
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kalbe Genexine Biologics
Deal Size: $1,100.0 million Upfront Cash: $27.0 million
Deal Type: Licensing Agreement February 18, 2021
Details:
Genexine expects to obtain full data from a Phase I trial of its DNA vaccine GX-19 late this year or early next year, while starting a Phase IIa study within this year and concurrent Phase IIb and III trials in the first half of next year.
Lead Product(s): GX-19
Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
